Rahbari and colleagues demonstrated that VEGFA-targeted therapy in metastatic CRC exacerbates the hypoxic TME, leading to hyaluronic acid and sulphated glycosaminoglycans (sGAGs) accumulation. This evidence concerns the gene VEGFA and colorectal carcinoma.